Myasthenia Gravis Steroid Regimens and Relapse Risk from a Real-World Cohort Study

Data Sheet 1 from a real-world cohort study by Yangyu Huang, last updated May 2026, investigates steroid therapy in myasthenia gravis. The dataset likely contains patient-level data from a prospective registry of 209 patients followed for a median of 54.0 months, where 113 experienced relapses. It analyzes associations between three steroid tapering regimens, steroid withdrawal, and relapse risk.

Use Cases

• Model relapse risk based on steroid dosing regimens identified in the study.
• Assess the impact of steroid withdrawal versus low-dose maintenance therapy on patient outcomes.
• Identify predictors of relapse, such as requiring a maximum induction dose >0.83 mg/kg.
• Validate group-based trajectory modeling (GBTM) for categorizing treatment patterns in clinical data.

Strengths

• Contains data from 209 patients followed for a median of 54.0 months.
• Includes results from propensity score matching (PSM) analysis on 68 patients who withdrew steroids.
• Defines three distinct steroid regimens based on baseline disease severity using group-based trajectory modeling.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data may reflect temporal and source bias inherent to the specific registry used.

Provenance

Source

Yangyu Huang via figshare.

Collection Method

Data derived from a prospective patient registry.

Freshness

Last updated 2026-05-13 04:41:21; freshness should be verified.